drugset / Trial / NCT03733470
Hypoxic Pulmonary Vasoconstriction Pilot Study
Phase 4
Completed
22 enrolled
Eric A. Hoffman
National Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedSingle-groupOpen-labelBasic science
Summary
The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.
Timeline
- Start
- 2011-06-29
- Primary completion
- 2014-01-13
- Completion
- 2014-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sildenafil | Unknown | 20 mg | — |